2. Signaling Pathways
  3. GPCR/G Protein
  4. Bradykinin Receptor
  5. Bradykinin B1 Receptor (B1R) Isoform
  6. Bradykinin B1 Receptor (B1R) Antagonist

Bradykinin B1 Receptor (B1R) Antagonist

Bradykinin B1 Receptor (B1R) Antagonists (7):

Cat. No. Product Name Effect Purity
  • HY-15039
    SSR240612
    		Antagonist 98.72%
    SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
  • HY-P4676A
    Lys-(Des-Arg9,Leu8)-Bradykinin TFA
    		Antagonist
    Lys-(Des-Arg9,Leu8)-Bradykinin TFA is a selective bradykinin B1 receptor (BDKRB1) antagonist. Lys-(Des-Arg9,Leu8)-Bradykinin TFA inhibits local inflammatory edema. Lys-(Des-Arg9,Leu8)-Bradykinin TFA induces the production of systemic acute-phase proteins. Lys-(Des-Arg9,Leu8)-Bradykinin TFA is applicable to research related to peptidoglycan-polysaccharide-induced acute arthritis.
  • HY-P5518A
    [Des-Arg10]-HOE I40 TFA
    		Antagonist 99.84%
    [Des-Arg10]-HOE I40 TFA is a potent bradykinin B1 receptor antagonist.
  • HY-P3232
    B 9430
    		Antagonist
    B 9430 is a potent bradykinin B1/B2 receptor antagonist.
  • HY-P2109
    JMV-1645
    		Antagonist
    JMV-1645 is a potent and selective B1 bradykinin receptor antagonist with a Ki value of 0.023 nM on the human cloned B1 receptor. JMV-1645 can be utilized in trauma and infection research.
  • HY-15042A
    (Rac)-MK 0686
    		Antagonist
    (Rac)-MK 0686 is the racemate of MK 0686. MK 0686 is a bradykinin B1 receptor antagonist.
  • HY-P1650
    Breceptin
    		Antagonist
    Breceptin (B 9870) is an antagonist of the bradykinin B1/B2 receptor (B1/B2R). Breceptin exhibits an irreversible antagonist effect on B2R, inhibiting the vasodilation induced by Bradykinin (HY-P0206) in the rabbit carotid vein contraction experiment. B-9870 shows partial agonist properties in HEK 293 cells with high expression of B2R, and can activate ERK1/2 phosphorylation, calcium ion mobilization, arachidonic acid release, and receptor internalization. Breceptin can be used in research to inhibit breast cancer and non-small cell lung cancer.